ORILISSA 150 mg QD
Demonstrated safety profile
Adverse reactions in ≥5% of subjects and their corresponding discontinuation rates1-5*


The most common serious adverse events reported with ORILISSA in ELARIS EM-1 and EM-2 included appendicitis (0.3%), abdominal pain (0.2%), and back pain (0.2%).1
0.2% of patients treated with ORILISSA 150 mg QD discontinued therapy due to serious adverse reactions compared to 0.5% receiving placebo.1
*Adverse reactions that occurred at a greater incidence than placebo in either ORILISSA dose group in ELARIS EM-1 and ELARIS EM-2.

Low discontinuation rates due to any adverse reaction1,5
ORILISSA 150 mg QD
Placebo
The most common serious adverse events reported with ORILISSA in ELARIS EM-1 and EM-2 included appendicitis (0.3%), abdominal pain (0.2%), and back pain (0.2%).1
0.2% of patients treated with ORILISSA 150 mg QD discontinued therapy due to serious adverse reactions compared to 0.5% receiving placebo.1
*Adverse reactions that occurred at a greater incidence than placebo in either ORILISSA dose group in ELARIS EM-1 and ELARIS EM-2.

ORILISSA 200 mg BID

The most common serious adverse events reported with ORILISSA in ELARIS EM-1 and EM-2 included appendicitis (0.3%), abdominal pain (0.2%), and back pain (0.2%).1
0.2% of patients treated with ORILISSA 200 mg BID discontinued therapy due to serious adverse reactions compared to 0.5% received placebeo.1
*Adverse reactions that occurred at a greater incidence than placebo in either ORILISSA dose group in ELARIS EM-1 and ELARIS EM-2.

The most common serious adverse events reported with ORILISSA in ELARIS EM-1 and EM-2 included appendicitis (0.3%), abdominal pain (0.2%), and back pain (0.2%).1
0.2% of patients treated with ORILISSA 200 mg BID discontinued therapy due to serious adverse reactions compared to 0.5% receiving placebo.1
*Adverse reactions that occurred at a greater incidence than placebo in either ORILISSA dose group in ELARIS EM-1 and ELARIS EM-2.
Low discontinuation rates due to any adverse reaction1,5
ORILISSA 200 mg BID
Placebo
The most common serious adverse events reported with ORILISSA in ELARIS EM-1 and EM-2 included appendicitis (0.3%), abdominal pain (0.2%), and back pain (0.2%).1
0.2% of patients treated with ORILISSA 200 mg BID discontinued therapy due to serious adverse reactions compared to 0.5% receiving placebo.1
*Adverse reactions that occurred at a greater incidence than placebo in either ORILISSA dose group in ELARIS EM-1 and ELARIS EM-2.
The most common serious adverse events reported with ORILISSA in ELARIS EM-1 and EM-2 included appendicitis (0.3%), abdominal pain (0.2%), and back pain (0.2%).1
0.2% of patients treated with ORILISSA 200 mg BID discontinued therapy due to serious adverse reactions compared to 0.5% receiving placebo.1
*Adverse reactions that occurred at a greater incidence than placebo in either ORILISSA dose group in ELARIS EM-1 and ELARIS EM-2.
Low discontinuation rates due to any adverse reaction1,5